These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37242998)

  • 1. Humoral Response after a Fourth Dose with mRNA-1273 in Healthcare Workers with and without a History of SARS-CoV-2 Infection and Previously Vaccinated with Two Doses of BBIBP-CorV Plus BNT162b2 Vaccine.
    Gómez de la Torre JC; Hueda-Zavaleta M; Cáceres-DelAguila JA; Muro-Rojo C; Cruz-Escurra N; Benítes-Zapata VA
    Vaccines (Basel); 2023 Apr; 11(5):. PubMed ID: 37242998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the Humoral Immune Response of a Heterologous Vaccination between BBIBP-CorV and BNT162b2 with a Temporal Separation of 7 Months, in Peruvian Healthcare Workers with and without a History of SARS-CoV-2 Infection.
    Hueda-Zavaleta M; Gómez de la Torre JC; Cáceres-Del Aguila JA; Muro-Rojo C; De La Cruz-Escurra N; Arenas Siles D; Minchón-Vizconde D; Copaja-Corzo C; Bardales-Silva F; Benites-Zapata VA; Rodriguez-Morales AJ
    Vaccines (Basel); 2022 Mar; 10(4):. PubMed ID: 35455251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralizing Antibodies as Predictors of Vaccine Breakthrough Infection in Healthcare Workers Vaccinated with or without a Heterologous Booster Dose: A Cohort Study during the Third COVID-19 Wave in Peru.
    Hueda-Zavaleta M; Gómez de la Torre JC; Cáceres-DelAguila JA; Muro-Rojo C; De La Cruz-Escurra N; Copaja-Corzo C; Aragón-Ayala CJ; Benítes-Zapata VA
    Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody and T Cell Responses against SARS-CoV-2 Elicited by the Third Dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster Vaccination Strategy.
    Matula Z; Gönczi M; Bekő G; Kádár B; Ajzner É; Uher F; Vályi-Nagy I
    Vaccines (Basel); 2022 Mar; 10(4):. PubMed ID: 35455288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru.
    Vargas-Herrera N; Fernández-Navarro M; Cabezudo NE; Soto-Becerra P; Solís-Sánchez G; Escobar-Agreda S; Silva-Valencia J; Pampa-Espinoza L; Bado-Pérez R; Solari L; Araujo-Castillo RV
    PLoS One; 2022; 17(10):e0268419. PubMed ID: 36251630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humoral response after a BNT162b2 heterologous third dose of COVID-19 vaccine following two doses of BBIBP-CorV among healthcare personnel in Peru.
    Montero S; Urrunaga-Pastor D; Soto-Becerra P; Cvetkovic-Vega A; Guillermo-Roman M; Figueroa-Montes L; Sagástegui AA; Alvizuri-Pastor S; Contreras-Macazana RM; Apolaya-Segura M; Díaz-Vélez C; Maguiña JL
    Vaccine X; 2023 Aug; 14():100311. PubMed ID: 37207103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial.
    Wu JD; Li JX; Liu J; Wang HM; Zhou GH; Li J; Wu D; Chen X; Feng Y; Qi XY; Wang X; Gou JB; Ma TL; Yang XY; Xu LF; Wan P; Zhu T; Wang ZF; Zhu FC;
    Lancet Infect Dis; 2023 Sep; 23(9):1020-1030. PubMed ID: 37216958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals.
    Mallah SI; Alawadhi A; Jawad J; Wasif P; Alsaffar B; Alalawi E; Mohamed AM; Butler AE; Alalawi B; Qayed D; Almahari SA; Mubarak A; Mubarak A; Saeed S; Humaidan A; Kumar N; Atkin S; Alqahtani M
    Vaccine; 2023 Mar; 41(12):1925-1933. PubMed ID: 36725431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the Efficacy of BBIBP-CorV Inactivated Vaccine Combined with BNT62b2 mRNA Booster Vaccine.
    Rákóczi É; Magócs G; Kovács S; Nagy B; Szűcs G; Szekanecz Z
    Diagnostics (Basel); 2023 Feb; 13(3):. PubMed ID: 36766663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the kinetics and magnitude of antibody responses to different SARS-CoV-2 proteins in Sinopharm/BBIBP-CorV vaccinees following the BNT162b2 booster or natural infection.
    Jeewandara C; Aberathna IS; Dayarathna S; Nimasha T; Ranasinghe T; Jayamali J; Kamaladasa A; Karunanada M; Perera L; Ogg GS; Malavige GN
    PLoS One; 2022; 17(10):e0274845. PubMed ID: 36227884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine.
    Chansaenroj J; Suntronwong N; Kanokudom S; Assawakosri S; Yorsaeng R; Vichaiwattana P; Klinfueng S; Wongsrisang L; Srimuan D; Thatsanatorn T; Thongmee T; Auphimai C; Nilyanimit P; Wanlapakorn N; Sudhinaraset N; Poovorawan Y
    Vaccines (Basel); 2022 Jul; 10(7):. PubMed ID: 35891235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humoral Immune Response Induced by the BBIBP-CorV Vaccine (Sinopharm) in Healthcare Workers: A Cohort Study.
    Gómez de la Torre JC; Cáceres-DelAguila JA; Muro-Rojo C; De La Cruz-Escurra N; Copaja-Corzo C; Hueda-Zavaleta M; Arenas Siles D; Benites-Zapata VA
    Trop Med Infect Dis; 2022 Apr; 7(5):. PubMed ID: 35622693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Homologous and Heterologous Vaccine Boosters With SARS-CoV-2 Infection in BBIBP-CorV Vaccinated Healthcare Personnel.
    Park S; Gatchalian KK; Oh H
    Cureus; 2022 Jul; 14(7):e27323. PubMed ID: 36043010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durability of anti-spike antibodies after vaccination with mRNA SARS-CoV-2 vaccine is longer in subjects with previous infection: could the booster dose be delayed?
    Stellini R; Gianello R; Gomarasca W
    Infection; 2022 Dec; 50(6):1573-1577. PubMed ID: 35391649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the reactogenicity and immunogenicity between two-dose mRNA COVID-19 vaccine and inactivated COVID-19 vaccine followed by an mRNA vaccine in children aged 5-11 years.
    Wanlapakorn N; Kanokudom S; Phowatthanasathian H; Chansaenroj J; Suntronwong N; Assawakosri S; Yorsaeng R; Nilyanimit P; Vichaiwattana P; Klinfueng S; Thongmee T; Aeemjinda R; Khanarat N; Srimuan D; Thatsanatorn T; Chantima W; Pakchotanon P; Duangchinda T; Sudhinaraset N; Poovorawan Y
    J Med Virol; 2023 May; 95(5):e28758. PubMed ID: 37212319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon.
    Moghnieh R; Mekdashi R; El-Hassan S; Abdallah D; Jisr T; Bader M; Jizi I; Sayegh MH; Rahman Bizri A
    Vaccine; 2021 Nov; 39(46):6713-6719. PubMed ID: 34656379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homologous booster immunization with an inactivated vaccine induced robust antibody response in healthcare workers: A retrospective study.
    Wen GP; Zhu M; Li LR; Li XJ; Ye HM; Zhou YL
    Front Immunol; 2023; 14():1099629. PubMed ID: 36817474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mix-and-match COVID-19 vaccines trigger high antibody response after the third dose vaccine in Moroccan health care workers.
    Amellal H; Assaid N; Akarid K; Maaroufi A; Ezzikouri S; Sarih M
    Vaccine X; 2023 Aug; 14():100288. PubMed ID: 37008956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine.
    Cucunawangsih C; Wijaya RS; Lugito NPH; Suriapranata I
    Int J Infect Dis; 2022 May; 118():116-118. PubMed ID: 35192955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.